Emcure, Intas Indian IPOs to test pharma investor appetite
This article was originally published in Scrip
Executive Summary
Two of India's top 15 drug companies by market share - Emcure Pharmaceuticals and Intas Pharmaceuticals - have filed for initial public offerings amid some general concern that the pharmaceutical sector may no longer be a blind defensive play. But industry experts nevertheless believe that investor enthusiasm is unlikely to be dimmed for the proposed offerings, which are also expected to facilitate the part exits of leading private equity firms.